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Increase in experimental infarct size with 
digoxin in a canine model of myocardial 
ischemia-reperfusion injury 
In the present study, dogs were pretreated with intravenous digoxin, 0.0125 mg/kg/day, for 6 to 
7 consecutive days to achieve clinically relevant serum concentrations; untreated animals were 
used as control subjects. After pretreatment, nine digoxin-pretreated dogs and nine control dogs 
were anesthetized and subjected to a 80minute occlusion of the left circumflex coronary artery, 
followed by 6 hours of reperfuaion. Anatomic myocardial infarct site, expressed as a percentage 
of the areas at risk of infarction and as a percentage of the total left ventricle were: 
20.2 + 3.3% control vs 35.4 + 6.2% digoxin-pretreated (p < 0.05) and 8.6 2 1.3% control va 
14.7 f 2.5% dlgoxln-pretreated (p < 0.05), respectively (2.04 + 0.37 ng/mi serum digoxln). 
Regional myocardial blood flow in the nonlachemic and ischemic zones tended to be lower in 
digoxin-pretreated than in control animals at baseline testing and were significantly reduced in 
the anterlor aubendocardial sites of digoxln-pretreated dogs during iachemla and reperfualon. 
These data suggest that an exacerbation or enhancement of myocardial. ischemial-reperfusion 
in)ury may occur in the presence of clinically observable serum digoxin concentratlona. (AM HEART 
J 1988;115:1171.) 
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Previous investigation in this laboratory have exam- 
ined the effects of clinically relevant serum digoxin 
concentrations, achieved by multiday pretreatment 
regimens, on the frequency and severity of ventricu- 
lar arrhythmias occurring in canine models of myo- 
cardial ischemic injury.lm4 In conscious dogs with 
recent anterior myocardial infarction, digoxin pre- 
treatment was associated with a significantly 
enhanced incidence of ventricular fibrillation and 
ischemic post infarction death in response to an 
acute ischemic episode occurring at a site remote 
from the area of previous myocardial injury.’ The 
digoxin-associated enhancement of ischemic postin- 
farction mortality was reduced significantly by the 
subacute ablation of the left stellate ganglion2 and 
by acute beta-adrenoceptor blockade with nadolol, 
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suggesting an involvement of sympathetic nervous 
activity in the arrhythmogenic actions of “therapeu- 
tic” digoxin in this preparation. In a recent study, 
using conscious dogs without previous myocardial 
ischemic injury, the in situ development of acute 
posterolateral ischemia in the presence of clinically 
relevant serum digoxin concentrations resulted in 
the development of ventricular ectopic activity at 1 
to 3 days after infarction that was less sensitive to 
suppression with conventional antiarrhythmic ther- 
apy compared to control animals subjected to poste- 
rolateral myocardial ischemia and infarction but not 
pretreated with digoxin.4 In the latter study, an 
examination of posterolateral myocardial infarct 
sizes at the conclusion of antiarrhythmic drug test- 
ing suggested that larger myocardial infarctions, 
expressed as a percentage of the total left ventricle, 
had evolved in the digoxin-pretreated group.4 
In the present study, the effects of clinically 
relevant serum concentrations of digoxin, achieved 
by a 6- to 7-day pretreatment regimen, on the extent 
of developing myocardial infarction were evaluated 
in an anesthetized canine model of regional myocar- 
dial ischemia-reperfusion injury. In this prepara- 
tion, the duration of regional ischemic injury was 
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controlled and equivalent in both the digoxin- 
pretreated and control groups, and the resulting 
myocardial infarct sizes were quantitated in terms of 
the total left ventricle and the area at risk of 
myocardial infarction. Regional myocardial blood 
flow was determined with the use of radiotracer- 
labeled microspheres in nonischemic and ischemic 
areas of myocardium to determine whether equiva- 
lent severities of ischemia were present in the digox- 
in-pretreated and control groups and to ascertain 
the effects of digoxin pretreatment on regional 
myocardial blood flow. 
METHODS 
Experimental groups. Nineteen male mongrel dogs 
were randomly assigned to either a treatment group that 
received intravenous digoxin (0.0125 mg/kg/day, n = 10, 
14.1 * 0.6 kg) or a control group that received no inter- 
vention (n = 9, 15.7 -t 1.0 kg). In digoxin-treated animals, 
the drug was given as a peripheral intravenous infusion 
into a radial foreleg vein on six to seven consecutive 
afternoons during the pretreatment period. After the 
pretreatment period and immediately before the induc- 
tion of anesthesia (see below), peripheral blood samples 
were obtained for determination of serum electrolyte 
concentrations in digoxin-pretreated and control animals 
and for determination of serum digoxin concentrations in 
digoxin-pretreated animals. 
Surgical preparation. Digoxin-pretreated and control 
animals were anesthetized with Dial-urethane solution 
(40% ethylurea, 10% allobarbital, 40% urethane; 0.6 
ml/kg intravenously), and the lungs were ventilated with 
room air by means of a cuffed endotracheal tube and a 
Harvard respirator. Cannulae were inserted into the left 
common carotid and right femoral arteries for withdrawal 
of reference arterial samples for determinations of myo- 
cardial blood flow; the left femoral artery was cannulated 
for measurement of systemic arterial pressure. A left- 
sided thoracotomy was performed in the fifth intercostal 
space, and the heart was suspended in a pericardial cradle. 
Catheters were placed into the left atrium for measure- 
ment of left atria1 pressure and for injection of radiola- 
beled microspheres for measurement of regional blood 
flow. The proximal left circumflex coronary artery was 
dissected free to allow placement of an electromagnetic 
flow probe (Carolina Medical Electronics, King, N. C.) for 
measurement of coronary artery blood flow. Lead II ECG, 
systemic arterial pressure, left atria1 pressure, and left 
circumflex coronary artery blood flow were recorded.on a 
model 7 polygraph (Grass Instruments, Quincy, Mass.). 
After a stabilization period of 30 minutes and injection 
of radiolabeled microspheres for determination of baseline 
regional myocardial blood flow, a critical stenosis of silk 
suture was applied to the proximal left circumflex coro- 
nary artery such that the maximum hyperemic response to 
a lo-second occlusion of the coronary artery was attenu- 
ated approximately 50%, whereas basal coronary artery 
blood flow was unaffected. Regional posterolateral myo- 
cardial ischemia was then produced by occluding the 
proximal left circumflex coronary artery for 60 minutes by 
means of a silicone tubing snare, followed by restoration of 
blood flow for a period of 6 hours. The critical stenosis was 
removed after 30 minutes of reperfusion. The critical 
stenosis was used in the present study to reduce the 
incidence of ventricular fibrillation during the early reper- 
fusion period.5 
Postmortem determination of infarct size. After the 
6-hour reperfusion period, the anesthetized dogs were 
killed by applying a supramaximal electric current to the 
surface of the left ventricle for induction of ventricular 
fibrillation. Each heart was excised rapidly and prepared 
for quantification of infarct size. A dual-perfusion tech- 
nique was used to determine the size of the infarcted mass, 
which wasexpressed as a percentage of the anatomic area 
at risk of infarction and as a percentage of the total left 
ventricle.6.g Cannulae were placed in the aorta above the 
coronary ostia and in the left circumflex coronary artery at 
the site of the occlusion. The left circumflex coronary 
artery bed was perfused with 1.5% triphenyltetrazolium 
chloride in 0.1 mol/L phosphate buffer (pH 7.4,37” C) at a 
pressure of 100 mm Hg. Simultaneously, the aorta was 
perfused with 0.5% Evans blue dye at the same perfusion 
pressure to delineate the nonischemic myocardium. After 
5 minutes of dual perfusion, the heart was cut into five 
sections perpendicular to the apex-base axis. The myocar- 
dium perfused by the left circumflex coronary artery 
constituted the area at risk of infarction and was identi- 
fied by the presence of a red coloration (because of the 
reduction of triphenyltetrazolium to a red formazan by 
dehydrogenase enzymes in viable cells) and the absence of 
blue dye. The infarcted area was apparent as tissue that 
lacked staining (because of the loss of dehydrogenase 
activity in irreversibly injured tissue) within the red area 
at risk.g The sections of left ventricle were traced onto a 
clear plastic overlay, and planimetry was performed to 
quantitate the size of the anatomic area at risk (as a 
percentage of the left ventricle) and the size of infarction 
(as percentages of the area at risk and the left ventricle) by 
means of an Apple IIE microcomputer and digitizing 
board. It is recognized that the simultaneous perfusion of 
both normal and ischemic myocardium at a pressure that 
exceeds the perfusion pressure of the ischemic zone in vivo 
may overestimate the area at risk of infarction. Also, some 
controversy exists regarding the correlation between the 
detection of irreversibly damaged tissue by means of 
triphenyltetrazolium staining as opposed to functional 
measurements.10 However, in the present study, there was 
good agreement between the delineation of the ischemic 
zone by measurements of blood flow and delineation by 
the dual-perfusion technique, suggesting that the degree 
of error was small. Previous studies also have shown an 
excellent correlation between triphenyltetrazolium stain- 
ing for quantification of infarct size and results of histo- 
logic examination of infarcts .6, gt 11, l2 Finally, any error that 
is encountered with the use of this technique for determi- 
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nation of infarct size should be similar in both treatment 
groups, because the same technique was used in each 
experiment. 
Regional myocardial blood flow measurements. 
Regional myocardial blood flow was measured with 15 Km 
diameter radiotracer-labeled microspheres (New England 
Nuclear, North Billerica, Mass., and 3M Corp., St. Paul, 
Minn.) by the reference withdrawal method.13 Regional 
myocardial blood flow was determined at four time points 
during the experiment (baseline, 50-minute occlusion, and 
l-hour and 4-hour reperfusion) by the randomly ordered 
injection of one of the following isotope-labeled micro- 
spheres at each time point: We, %c, lWn, or %r. 
Approximately one to two million microspheres were 
injected into the left atrium at each time point. Reference 
carotid and femoral arterial samples were obtained at a 
constant rate of 7.05 ml/min with a Harvard withdrawal 
pump (Harvard Apparatus, Millis, Mass.) The withdrawal 
of reference blood samples was initiated before the injec- 
tion of microspheres and was completed 90 seconds after 
flushing with 10 ml saline solution after injection of the 
microspheres. Each vial of microspheres was mixed by 
sonication and vortex agitation before injection, and ali- 
quots of the microsphere suspension were examined peri- 
odically under a microscope to ensure that adequate 
dispersal was being achieved. 
Three basal transverse rings of left ventricle were used 
for determinations of regional myocardial blood flow after 
overlay tracings were made for determinations of infarct 
size. Full-thickness sections were obtained from the left 
circumflex central ischemic and left anterior control non- 
ischemic areas. Each section of tissue was divided into 
three pieces (subendocardial, midmyocardial, and subepi- 
cardial) of equal thickness and mass (approximately 1 
gm). Tissue samples were placed in counting vials for the 
counting of radioactivity in a gamma scintillation counter 
(Tracer model 1185, Elk Grove, Ill.). After the counts in 
each tissue sample were corrected for background and 
overlapping counts, blood flow was calculated with the 
equation Qm = (Cm X Qr)/Cr, where Qm = myocardial 
blood flow (ml/min), Cm = counts/min in tissue samples, 
Qr = withdrawal rate of the reference arterial samples 
(ml/min), and Cr = counts/min in the reference arterial 
sample. Flow per gram of tissue (ml/min/gm) was calculat- 
ed by dividing the tissue sample flow by the sample mass. 
Background and overlap corrections and blood flow calcu- 
lations were performed on an Apple II Plus microcomput- 
er. 
Exclusion criteria. The measurement of regional myo- 
cardial blood flow with radiotracer-labeled microspheres 
permits an accurate assessment of ischemic collateral 
blood flow during coronary artery occlusion. Previous 
studies7*14 have shown a critical dependence of the extent 
of evolving myocardial infarction on the magnitude of 
regional myocardial blood flow in ischemic myocardium, 
and hence the necessity to ascertain and control for 
abnormally high ischemic regional myocardial blood flow 
resulting from excessive collateralization in experimental 
myocardial infarct size determinations. In the present 
study, a total of 19 dogs (10 digoxin pretreat,ed and nine 
control) were entered into the experimental protocol. 
During postmortem assessment of regional myocardial 
blood flow in the central ischemic region, one digoxin- 
pretreated dog was determined to have maintained an 
excessively high degree of regional myocardial blood dur- 
ing coronary artery occlusion compared to both the 
remaining cohort of digoxin-pretreated dogs (n = 9) and 
the untreated control group (n = 9). During left circum- 
flex coronary artery occlusion, subendocardial blood flow 
in the central ischemic region of the aforementioned 
“high-flow” animal was 0.192 ml/min/gm compared to 
subendocardial flow values of 0.04 +- 0.01 and 0.03 i 0.01 
ml/min/gm in the remaining digoxin-pretreated and con- 
trol animals, respectively. Transmural myocardial blood 
flow in the “high-flow” animal during coronary artery 
occlusion was 0.322 ml/min/gm compared to transmural 
blood flow values of 0.07 rt 0.02 and 0.06 ?Z 0.01 ml/ 
min/gm in the remaining digoxin-pretreated and control 
animals, respectively. The large magnitude of difference 
in regional blaod flow values for the one digoxin- 
pretreated “high-flow” animal and the remaining cohort 
of nine digoxin-pretreated animals strongly suggests that 
the high values for regional myocardial blood flow during 
coronary artery occlusion observed in the one animal were 
not the result of a specific treatment effect but rather the 
result of excessive collateralization in that one animal. 
Therefore, the data for the one digoxin-pretreated animal 
with high values for ischemic collateral myocardial blood 
flow have been excluded from consideration and, unless 
otherwise indicated, analyses of the data on hemodynamic 
and myocardial infarct size presented in this report are 
based on the results obtained from nine digoxin- 
pretreated and nine untreated control animals. 
Determination of serum digoxin and serum electrolyte 
concentrations. Blood samples for determination of 
serum digoxin, sodium, and potassium concentrations 
were obtained at the end of the pretreat,ment period and 
immediately before the induction of anesthesia (approxi- 
mately 16 hours after the preceding drug administration 
in the digoxin-pretreated group). For animals in the 
digoxin-pretreated group, venous blood samples were 
obtained from a radial vein not used previously for drug 
administration. Serum sodium and potassium concentra- 
tions were determined for the digoxin-pretreated and 
control animals by means of a flame photometer (model 
IL-143, Instrumentation Laboratory Jnc, Boston, Mass.). 
Serum digoxin concentrations were determined in the 
digoxin-pretreated group by means of a radioimmunoas- 
say technique in the Ligand Assay Laboratory at The 
University of Michigan Medical School. with the use of 
sheep antidigoxin antiserum. 
Analysis of data. Hemodynamic data (heart rate, sys- 
temic arterial pressure, left atria1 pressure, and left cir- 
cumflex coronary artery blood flow) were analyzed at 
seven time points: (1) baseline, (2) 15 minutes after left 
circumflex coronary artery occlusion, (3 I 50 minutes after 
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Table 1. Hemodynamic data at baseline, during left circumflex coronary artery occlusion, and after left circumflex 
coronary artery reperfusion 
Hemo- LCx occlusion 
dynamic Base- 
LCx reperfusion 
data line 15 min 50 min 15 min 1 hr 4 hr 6 hr 
Heart rate (beats/min) 
CNT 139 -+ 6 143 +_ 7 144 + 7 129 +. 5 132 rt 6 147 f 8 153 rt 11 
DIG 152 + 10 147 2 9 147 k 8 136 k 8 137 + 8 146 f 11 149 f 12 
Mean arterial pressure (mm Hg) 
CNT 106 f 6 95 f 6* 95 * 7* 88 2 5** 87 2 5** 87 k 6** 87 k 7** 
DIG 98 + 6 86 + 6** 81 + 6** 73 * 4** t 78 * 4** 81 f 4** 72 + 4** 
Rate-pressure product (HR X MAP, X 103) 
CNT 15.0 + 1.3 13.7 * 1.2 13.9 + 1.4 11.5 + 0.9** 11.5 + 0.9** 12.8 -t 1.2 13.7 f 2.0 
DIG 15.2 + 1.7 12.9 k 1.4 12.3 + 1.5* 10.0 * 1.0** 10.7 * 0.9** 12.0 1.4** + 11.1 +- 1.3** 
Left atrial pressure (mm Hg) 
CNT 7.7 f 1.2 8.7 f 0.9 10.3 r 1.2 7.4 -t- 0.8 6.6 3t 1.0 7.4 f 0.8 6.6 + 1.0 
DIG 7.3 * 1.1 8.8 * 1.5 8.3 + 1.6 7.3 k 0.7 8.4 -c 1.5 7.3 + 0.7 8.4 + 1.5 
LCx blood flow (ml/min) 
CNT 16.6 f 1.6 0** 0** 15.1 * 1.1 13.7 + 1.1 12.7 k 2.0 9.9 f 0.9** 
DIG 13.7 * 1.5 0** 0** 14.7 iz 2.1 12.8 rt 1.5 8.4 * 1.1** 7.6 + l.l** 
Data are mean k SE; for all parameters, n = 9. 
CNT = Untreated control group; DIG = digorin-pretreated group; HR = heart rate; LCx = left circumflex coronary artery; MAP = mean arterial 
pressure. 
*p < 0.05 and **p < 0.01 compared to appropriate baseline value within group (repeated-measures analysis of variance followed by Dunnett’s test for 
multiple comparisons). tp < 0.05 comparing DIG vs CNT parameters at specified time point (unpaired Student’s t test). 
coronary artery occlusion, (4) 15 minutes after coronary 
artery reperfusion, (5) 1 hour after coronary artery reper- 
fusion, (6) 4 hours after coronary artery reperfusion, and 
(7) 6 hours after coronary artery reperfusion. A rate- 
pressure product (heart rate x mean arterial pressure) 
was calculated at each time point as an iridex of myocar- 
dial oxygen consumption. 7, I5 Regional myocardial blood 
flow was determined at: (1) baseline, (2) 50 minutes after 
left circumflex coronary artery occlusion, (3) 1 hour after 
coronary artery reperfusion, and (4) 4 hours after coronary 
artery reperfusion. For the hemodynamic and regional 
blood flow data, comparisons for a given parameter within 
a group relative to the baseline value were made by means 
of a repeated-measures analysis of variance, followed by a 
Dunnett’s test for multiple comparisons to one control 
(baseline) value. Comparisons between the two treatment 
groups at a given time point were made by means of a 
two-tailed, unpaired Student’s t test. Comparisons 
between the two groups for infarct size also were made by 
means of the two-tailed unpaired Student’s t test. The 
incidences of ventricular fibrillation in the digoxin pre- 
treatment and control groups were compared by means of 
Fisher’s exact test for binomial distribution. For evalua- 
tion of direct relationships between myocardial infarct 
size and hemodynamic or blood flow parameters, linear 
regression was performed and correlation coefficients were 
evaluated. The significance of the regression coefficient 
was tested by the calculation of a probability (p) value, 
and 95% confidence intervals were determined for mean 
(x,y) values for the regression lines to determine overlap. 
For all comparisons, p < 0.05 was considered statistically 
significant. All data are expressed as mean f standard 
error. 
RESULTS 
Serum digoxin and electrolyte concentrations. 
Serum digoxin concentrations determined in the 
digoxin-pretreated animals were 2.04 +- 0.37 rig/ml 
after a mean treatment duration of 6.7 + 0.3 days. 
Serum sodium (125.4 + 1.5 and 119.9 f 3.0 mEq/L) 
and potassium (4.35 +- 0.10 and 4.25 f 0.12 mEq/L) 
concentrations were similar in the control and 
digoxin-pretreated groups, respectively. 
Hemodynamic parameters. Hemodynamic data are 
summarized in Table I. At baseline and during the 
period of left circumflex coronary artery occlusion, 
no significant between-group differences in mea- 
sured hemodynamic parameters or in calculated 
rate-pressure product were noted for the digoxin- 
pretreated and control groups, although the baseline 
value for left circumflex coronary artery blood flow 
tended to be reduced in the digoxin-pretreated 
group (-18% of control values; p = 0.20) compared 
to the control group value (Table I). Both treatment 
groups displayed similar hemodynamic profiles in 
response to left circumflex coronary artery reperfu- 
sion after regional myocardial &hernia, with the 
only significant between-group difference being a 
reduction in mean arterial pressure in the digoxin- 
pretreated group relative to the control value 
(p < 0.05) at the 15-minute postreperfusion time 
point (Table I). During the reperfueion period, 
within-group comparisons to baseline values indi- 
cated progressive and significant declines in mean 
Volume 115 
Number 6 Digoxin and AM size 1175 
Table II. Myocardial blood flow in the central ischemic area (left circumflex distribution) at baseline, during left 
circumflex coronary artery occlusion, and after left circumflex coronary artery reperfusion 
- 





Subendocardial MBF (ml/min/gm) 
CNT 0.62 k 0.05 
DIG 0.56 t 0.07 
Midmyocardial MBF (ml/min/gm) 
CNT 0.61 -+_ 0.04 
DIG 0.57 * 0.07 
Subepicardial MBF (ml/min/gm) 
CNT 0.54 -t 0.03 
DIG 0.49 + 0.06 
50 min. 
0.03 * 0.01** 
0.04 + 0.01** 
0.05 k o.oz** 
0.06 -+ 0.02** 
0.08 + 0.02** 
0.10 ? 0.03** 
1 hr 
0.77 * 0.14 
0.60 t 0.10 
0.58 -+ 0.09 
0.59 + 0.06 
0.42 + 0.04 
0.51 + 0.07 
4 hr 
-.-^ --- 
0.38 _+ 0.05’ 
0.29 + 0.04** 
0.42 ” 0.07 
0.;10 - 0.03** 
0.40 i 0.05 
0.::7 * 0.04 
Endocardial/epicardial ratio 
CNT 1.20 2 0.04 0.46 t O.lO* 1.96 +- 0.40* 0.99 c 0.12 
DIG 1.19 -+ 0.07 0.41 -+ 0.07** 1.27 + 0.20 0.1’(4 i; 0.14 
Data are mean + SE; for all parameters, n = 9. 
CNT = Untreated control group; DIG = digoxin-pretreated group; LCx = left circumflex coronary artery; MBF = myocardial blood How. 
*p < 0.05 and **p < 0.01 compared to appropriate baseline value within group (repeated-measures analysis of variance followed Iw Ikmnett’s test for 
multiple comparisons). There were no significant differences between DIG and CNT groups during any time points. 
Table Ill. Myocardial blood flow in nonischemic control area (left anterior distribution) at baseline, during left 





50 min 1 hr 4 hr 
Subendocardial MBF (ml/min/gm) 
CNT 0.70 zk 0.06 0.74 + 0.04 0.59 ” 0.04 V.64 k 0.05 
DIG 0.54 +_ 0.06 0.56 + 0.041 0.45 ” 0.05t 0.44 + 0.04t 
Midmyocardial MBF (ml/min/gm) 
CNT 0.67 + 0.08 0.68 +- 0.04 0.52 k 0.03* 0.58 + 0.04 
DIG 0.52 f 0.06 0.56 +- 0.04t 0.48 It 0.04 c: 47 + 0.05 
Subepicardial MBF (ml/min/gm) 
CNT 0.52 ? 0.06 0.53 t- 0.04 0.41 + 0.03 (‘“45 -t 0.04 




1.42 k 0.05 1.43 * 0.04 1.47 +- 0.05 ! .50 + 0.05 
1.28 * 0.08 1.28 k 0.08 1.24 + 0.13 ‘.28 + 0.09t 
Data are mean + SE; for all parameters, n = 9. 
CNT = Untreated control group; DIG = digoxin-pretreated group; LCx = left circumflex coronary artery; MBF = myocardial blood flow. 
*p < 0.05 compared to appropriate baseline value within group (repeated-measures analysis of variance followed by Dunnett’s t,est for multiple 
comparisons). tp < 0.05 and $p < 0.01 comparing DIG vs CNT parameter at specified time point (unpaired Student’s t test). 
arterial pressure, rate-pressure product, and left 
circumflex coronary artery blood flow in each treat- 
ment group. The onset and degree of reduction in 
the aforementioned hemodynamic parameters 
tended to be earlier and greater, respectively, com- 
pared to appropriate baseline values within the 
digoxin-pretreated group compared to the control 
group (Table I). 
Myocardial blood flow. Regional myocardial blood 
flow data from the ischemic left circumflex and 
nonischemic anterior areas are compared for the two 
treatment groups in Tables II and III, respectively. 
In the ischemic left circumflex region (Table II), 
there were no significant differences in regional 
blood flow between the digoxin-pretreated and con- 
trol groups at baseline testing, during the period of 
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Fig. 1. Posterolateral myocardial infarct sizes in digoxin- 
pretreated (DIG) and untreated control (CNT) animals 
after 60-minute occlusion of left circumflex coronary 
artery, followed by 6 hours of reperfusion. For both 
treatment groups, area at risk of infarction is expressed as 
percentage of left ventricle (ARILV); infarct zone size is 
expressed as percentages of area at risk (IZIAR) and of 
left ventricle (IZ/LV). Values are mean +- SE. 
left circumflex coronary artery occlusion, and during 
coronary artery reperfusion, although there was a 
tendency for the blood flow in the digoxin- 
pretreated group to be less than the control blood 
flow in the subepicardial tissue samples at baseline 
and during reperfusion. Similarly, there were no 
significant differences in endocardial/epicardial 
regional blood flow ratios between the digoxin- 
pretreated and control groups in the left circumflex 
region at any time point tested, although the endo- 
cardial/epicardial ratio for the control group at 1 
hour of left circumflex coronary artery reperfusion 
was markedly greater than the corresponding value 
in the digoxin-pretreated group (+54% of digoxin 
pretreatment value, p = 0.14) at this time point 
(Table II). Equivalent and significant reductions in 
regional myocardial blood flow occurred in all of the 
sampling regions within the digoxin-pretreated and 
control groups during the period of left circumflex 
coronary artery occlusion, suggesting the develop- 
ment of equal degrees of myocardial ischemia in the 
two treatment groups. At 4 hours after the com- 
mencement of left circumflex coronary artery reper- 
fusion, subendocardial and midmyocardial blood 
flow was significantly reduced (p < 0.01 for each 
sample area) relative to baseline values within the 
digoxin-pretreated group, whereas in the control 
group only subendocardial flow was reduced relative 
to baseline, and to a lesser extent than in the 
digoxin-pretreated group (p < 0.05). Endocardiall 
epicardial ratios in the left circumflex regions for 
both the digoxin-pretreated and control groups were 
reduced significantly and equivalently during left 
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Fig. 2. Posterolateral myocardial infarct sizes (expressed 
as percentages of area at risk) for digoxin-pretreated 
(DIG, open squares) and control (CNT, closed squares) 
preparations plotted as function of transmural regional 
myocardial blood flow (MBF) in ischemic left circumflex 
coronary artery distribution at 50 minutes of coronary 
artery occlusion. Simple regression lines (dashed lines), 
correlation coefficients, and probability values are super- 
imposed on graphs. 
circumflex coronary artery occlusion, reflecting the 
relatively greater vulnerability of the subendocar- 
dium to blood flow reduction after coronary artery 
ligation in both groups. Within the control group, 
the endocardial/epicardial ratio in the left circum- 
flex region was increased significantly relative to the 
baseline value at 1 hour after left circumflex coro- 
nary artery reperfusion, suggesting a marked 
enhancement in subendocardial blood flow early 
after reperfusion. A similar enhancement of suben- 
docardial blood flow early after reperfusion was not 
observed in the digoxin-pretreated group (Table 
II). 
In the nonischemic anterior region (Table III), 
there were no significant differences in regional 
myocardial blood flow between the two treatment 
groups at baseline testing, although blood flow in all 
three sampling regions tended to be reduced in the 
digoxin-pretreated group (-14 to -23% of control 
values) compared to the control group. Regional 
myocardial blood flow remained depressed in the 
digoxin-pretreated group relative to the control 
group during both the left circumflex coronary 
artery occlusion and reperfusion periods, with the 
values for regional blood flow in the digoxin- 
pretreated group becoming significantly reduced in 
the subendocardial 0, < 0.01) and midmyocardial 
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Fig. 3. Posterolateral myocardial infarct sizes (expressed 
as percentages of area at risk) for digoxin-pretreated 
(DIG, open squares) and control (CNT, closed squares) 
preparations plotted as function of rate-pressure product. 
Correlation coefficients for regression lines for both treat- 
ment groups (not shown) were not significant. 
@ < 0.05) regions during left circumflex coronary 
artery occlusion, and in the subendocardial region at 
both 1 hour (p < 0.05) and 4 hours (p < 0.05) of left 
circumflex coronary artery reperfusion, compared to 
corresponding control values. In the nonischemic 
region, the only significant deviation from the base- 
line values for regional blood flow within either 
treatment group was a reduction in midmyocardial 
flow (p < 0.05) at 1 hour after left circumflex coro- 
nary artery reperfusion in the control group. Endo- 
cardial/epicardial ratios for the digoxin-pretreated 
group in the nonischemic area were consistently less 
at all time points relative to control values, with the 
digoxin-pretreated endocardial/epicardial blood 
flow ratio significantly reduced 0, < 0.05) in com- 
parison to the control value at 4 hours after left 
circumflex coronary artery reperfusion. 
Size of myocardial infarction. The sizes of the 
developing myocardial infarctions for the digoxin- 
pretreated and untreated control groups are shown 
in Fig. 1. For both groups, the infarct zones are 
quantitated as percentages of both the anatomic 
area at risk (IZ/AR) and the left ventricle (IZ/LV). 
The sizes of the risk areas for both groups are 
quantitated as percentages of the left ventricle 
(AR/LV). Posterolateral myocardial infarct size, 
expressed as a percentage of the area at risk, was 
20.2 + 3.3% in untreated control animals vs 35.4 -t 
6.2% in the digoxin-pretreated group (p < 0.05). 
When the extent of ischemic injury was expressed as 
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Fig. 4. Posterolateral myocardial infarct sizes (expressed 
as percentages of left ventricIe) for digoxin-pretreated 
(DIG, open squares) and control (CNT, closed squares) 
preparations plotted as function of area at risk of infarc- 
tion expressed as percentage of left ventricle). Correlation 
coefficients for regression lines for both treatment groups 
(not shown) were not significant. 
a percentage of the left ventricle, infarct size was 
8.6 + 1.3% in the control group vs 14.7 -t 2.5% in 
the digoxin-pretreated group (p < 0.05). Regardless 
of the manner in which infarct size was quantitated, 
significantly larger myocardial infarctions devel- 
oped within the left circumflex coronary distribu- 
tions of digoxin-pretreated animals subjected to 
regional myocardial ischemia and reperfusion than 
in untreated control animals (Fig. 1). The anatomic 
areas at risk of infarction did not differ significantly 
between the digoxin-pretreated and untreated con- 
trol animals subjected to regional posterolateral 
myocardial ischemia and reperfusion (Fig. 1). 
Previous studies in this laboratory have used a 
maximum subepicardial ischemic collateral blood 
flow criterion of 0.2 ml/min/gm during the period of 
left circumflex coronary artery occlusion to identify 
animals with “adequate” degrees of ischemia. The 
application of this collateral blood flow criterion to 
the present study would result in the excl~ion of 
two digoxin-pretreated preparations with subepicar- 
dial collateral blood flows of 0.223 and 0.248 ml/ 
min/gm during coronary artery occlusion, whereas 
no control untreated preparations would be exclud- 
ed. Posterolateral myocardial infarct sizes in the 
animals not excluded by the collateral blood flow 
criterion are: (percentage of the area at risk) 20.2 A 
1178 Lynch et al. 
June 1988 
American Heart Journal 
3.3% in the control group vs 42.2 +- 5.3% in the 
digoxin-pretreated group (p < 0.01) and (percentage 
of the left ventricle) 8.6 + 1.3 % in the control group 
vs 17.1 -+ 2.2% in the digoxin-pretreated group 
(p < 0.01). Hence, significantly larger myocardial 
infarctions developed in the left circumflex coronary 
artery distributions of digoxin-pretreated animals 
subjected to regional myocardial ischemia and 
reperfusion than in untreated control animals 
regardless of the application of a maximal ischemic 
collateral blood flow criterion. 
Determinants of myocardial infarct size. Linear 
regression analyses were performed to evaluate the 
influence of the size of the area at risk of infarction, 
rate-pressure product, and ischemic collateral blood 
flow on myocardial infarct size. Myocardial infarct 
sizes within both the digoxin-pretreated and control 
groups were correlated significantly with transmural 
regional myocardial blood flow in the central is- 
chemic left circumflex distribution during coronary 
artery occlusion, with the infarct sizes in the digox- 
in-pretreated group being larger than those in the 
control group throughout the range of collateral 
blood flow values (Fig. 2). The infarct size-central 
ischemic regional blood flow regression lines for the 
two treatment groups were parallel, and the 95% 
confidence intervals did not overlap. In contrast, the 
myocardial infarct sizes in both treatment groups 
failed to correlate significantly with the rate-pres- 
sure product, an index of myocardial oxygen con- 
sumption (Fig. 3). Likewise, myocardial infarct sizes 
in the digoxin-pretreated and control groups failed 
to correlate significantly with the areas at risk of 
infarction, with the risk regions being relatively 
similar within and between groups (Fig. 4). 
Development of ventricular arrhythmias. The fre- 
quency and complexity of ventricular ectopic com- 
plexes varied markedly within both treatment 
groups during coronary artery occlusion and reper- 
fusion in this preparation; therefore, no attempt has 
been made to quantify and compare premature 
ventricular complex counts or grades of complexity. 
The incidence of ventricular fibrillation during the 
period of left circumflex coronary artery occlusion 
was two of nine (22%) in the digoxin-pretreated 
group and none of nine (0 % ) in the control group 
(P = not significant). Both of the digoxin-pretreated 
animals that developed ventricular fibrillation dur- 
ing left circumflex coronary artery occlusion under- 
went cardioversion by direct-current countershock. 
None of the animals in either treatment group had 
ventricular fibrillation during the reperfusion phase 
of this study. 
DISCUSSION 
Uncertainties regarding the potential detrimental 
actions of the cardiac glycosides in the setting of 
myocardial ischemic injury, particularly their influ- 
ence on postinfarction mortality,16-21 persist despite 
the long-standing use of this class of drugs for 
inotropic support of the failing heart. The contro- 
versies surrounding the therapeutic use of cardiac 
glycosides during myocardial ischemia and the evo- 
lution of myocardial infarction reside primarily in 
the potential for exacerbation or facilitation of the 
development of ischemic ventricular arrhythmias, as 
well as a possible aggravation of myocardial ischem- 
ic injury resulting from unfavorable effects on myo- 
cardial oxygen demand, coronary blood flow, or 
both.22-24 Results of previous studies in this laborato- 
ry, with the use of canine models of myocardial 
ischemic injury, have shown a significant propensity 
for clinically relevant serum concentrations of 
digoxin to increase the incidence of ischemic postin- 
farction mortality’ and to promote the development 
of ischemic ventricular ectopic activity that is less 
sensitive to suppression with conventional antiar- 
rhythmic agents.4 In the present study, pretreat- 
ment to achieve serum digoxin concentrations 
approximating the high range of therapeutic values 
resulted in an increase in the anatomic myocardial 
infarct size developing in response to a 60-minute 
period of regional myocardial ischemia followed by 6 
hours of reperfusion in an anesthetized, open-chest 
canine preparation. An evaluation of the effects of 
digoxin on the hemodynamic and regional myocardi- 
al blood flow determinants of myocardial infarct 
size, as well as a comparison of the present results 
with those of previous studies, is presented below. 
Hemodynamic effects of digoxin. The potential for 
digitalis to increase myocardial oxygen demand by 
virtue of a positive inotropic effect in the presence of 
a limited oxygen supply in the ischemic heart is 
central to the hypothesis that cardiac glycosides 
may exacerbate developing myocardial ischemic 
injury.22-24 However, the results of experimental 
assessments of the hemodynamic effects of acute 
digitalis administration during myocardial ischemia 
and acute myocardial infarction have yielded incon- 
sistent results. Early experimental studies in anes- 
thetized and conscious dogs showed no marked 
global hemodynamic effects with acutely adminis- 
tered cardiac glycosides during acute myocardial 
ischemia and subacutely after myocardial infarction, 
whereas global inotropic effects were seen 7 days 
after myocardial infarction.25s26 In anesthetized dogs, 
Banka et a12’ observed improvement in regional 
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contractile function in nonischemic and “border 
zone” myocardial areas, but not in ischemic areas, 
with an acute intravenous bolus and maintenance 
infusion of digoxin administered at times varying 
from 15 minutes to 2 hours after coronary artery 
occlusion. In contrast, Vatner at el.% reported signif- 
icant increases in regional contractile function in 
nonischemic, moderately ischemic, and ischemic 
myocardial zones in conscious dogs receiving oua- 
bain as an intravenous bolus injection 20 minutes 
after coronary artery occlusion. Recently, Banka et 
aLzg reported improvement in regional subendocar- 
dial and subepicardial contractile function in is- 
chemic myocardium in anesthetized dogs receiving 
intravenous ouabain 30 minutes after partial coro- 
nary artery ligation (50 % of baseline flow), whereas 
no improvement in regional function in ischemic 
tissue was noted with ouabain at 30 minutes after 
complete coronary artery ligation. It is noteworthy 
that no determinations of the metabolic costs asso- 
ciated with enhanced contractile performance pro- 
duced by acute digitalis in moderately ischemic or 
ischemic tissues were performed in the previous 
evaluations of Vatner et aLzs or Banka et al.,2g and 
there was no assessment of the effects of digitalis on 
regional function or myocardial oxygen consump- 
tion during more prolonged periods of regional 
myocardial ischemia. 
In the present study, the pretreatment of animals 
with digoxin for 6 to 7 days to achieve clinically 
relevant serum concentrations produced no marked 
effects on measured hemodynamic parameters at 
baseline testing after anesthesia and instrumenta- 
tion compared to untreated control animals. Fur- 
ther, no striking differences between groups were 
noted during the periods of regional myocardial 
ischemia and reperfusion for parameters such as 
heart rate, left atrial and systemic arterial pressures, 
and rate-pressure product, with the exception of a 
slight decrease in mean arterial pressure in digoxin- 
pretreated animals immediately after reperfusion of 
the ischemic myocardium. These hemodynamic data 
suggest no untoward effects of digoxin on the pre- 
load and afterload determinants of myocardial oxy- 
gen consumption that would account for an exacer- 
bation of myocardial ischemic-reperfusion injury in 
this preparation, and these data are consistent with 
the failure of previous experimental evaluations 
(cited above) to demonstrate marked global hemo- 
dynamic effects with digitalis in canine models of 
myocardial ischemic injury. In the present study, 
the within-group reductions in mean systemic arte- 
rial pressure, rate-pressure product, and left circum- 
flex coronary artery blood flow observed during the 
reperfusion period in both treatment groups likely 
are a reflection of the development of myocardial 
necrosis in the area of myocardium rendered is- 
chemic and reperfused. 
Effects of digoxin on myocardial blood flow. Consid- 
erable experimental and clinical evidence indicates 
that cardiac glycosides possess direct and/or neuro- 
genitally mediated coronary vasoconstrictor activi- 
ty”” that may tend, in theory, to aggravate ischemic 
injury by limiting myocardial oxygen s~pply.~v 24, 3o 
In both conscious and anesthetized dogs, in the 
absence of myocardial ischemic injury, the acute 
administration of digitalis preparations results in 
increases in coronary31.33 and systemic”4 vascular 
resistance. In a canine in situ isolated blood per- 
fused heart preparation, Gross et a1.3L observed 
increases in coronary vascular resistance and a 
redistribution of myocardial blood flow from the 
subendocardium to the subepicardium (i.e., an 
increased epicardial/endocardial blood flow ratio), 
which appeared to be dependent on concomitant 
elects on global contractile function after the acute 
intravenous administration of ouabain. The effects 
of digitalis on regional myocardial blood flow during 
myocardial ischemia and infarction however, are 
less well characterized. Sagar et aLs5 reported 
increases in coronary vascular resistance, in some 
instances resulting in ventricular fibrillation, after 
the acute intravenous administration of acetylstro- 
phanthidin or digoxin during acute global myocardi- 
al ischemia in anesthetized dogs, whereas Vatner et 
al.‘* observed increases in regional blood flow to 
normal, moderately ischemic, and ischemic regions 
after the acute intravenous administration of oua- 
bain after 20 minutes of coronary artery occlusion in 
conscious dogs. 
In the present study, absolute values for regional 
myocardial blood flow did not differ significantly 
between the digoxin-pretreated and control animals 
at baseline, although regional blood flow in both the 
anterior nonischemic and posterolateral ischemic 
areas, particularly in the subendocardial sections, 
tended to be decreased in the digoxin-pretreated 
group relative to the control group. In the left 
circumflex coronary artery distribution, subendo- 
cardial and midmyocardial regional blood flow was 
reduced to a greater extent within the digoxin- 
pretreated group compared to that within the con- 
trol group during late reperfusion. In the nonis- 
chemic left anterior distribution, absolute regional 
myocardial blood flow values were significantly low- 
er in the digoxin-pretreated group during left cir- 
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cumflex coronary artery occlusion (subendocardial 
and midmyocardial) and reperfusion (subendocar- 
dium at 1 and 4 hours) compared to the control 
group. Left circumflex coronary artery blood flow 
was also reduced earlier and to a greater degree 
during the late reperfusion period in the digoxin- 
pretreated group compared to the control group. 
Finally, the endocardial/epicardial blood flow ratios 
tended to be lower in the digoxin-preteated group 
than in the control group, both in the left circumflex 
distribution (during early and late reperfusion) and 
in the nonischemic anterior region (all time points), 
suggesting less coronary blood flow supply to the 
subendocardial region in digoxin-pretreated ani- 
mals, which is consonant with the findings of Gross 
et a1.31 The preceding findings suggest that pretreat- 
ment with digoxin may have limited regional coro- 
nary blood flow to the subendocardium, which 
inherently is more vulnerable to myocardial ischem- 
ic injury than other areas of the myocardium36; it 
may also have reduced the amount of available 
collateral coronary blood flow from the nonischemic 
region to the border areas of the ischemic zone. 
Either of the aforementioned effects may have 
contributed to an extension of myocardial infarct 
size in the present study. It must be noted, however, 
that the potential influence of the evolving postero- 
lateral myocardial infarctions must be considered in 
the interpretation of the regional blood flow data. 
Alterations in regional myocardial blood flow in the 
digoxin-pretreated animals, particularly in the left 
circumflex distribution during the late reperfusion 
period, may be caused by the development of signif- 
icantly larger myocardial infarctions in this region 
compared to control preparations. 
Effect of digoxin on myocardial ischemic injury. Rel- 
atively few experimental studies have directly evalu- 
ated the effect of digitalis on the severity or extent 
of an evolving myocardial infarction. In anesthetized 
dogs, Maroko et a1.37 observed an increase in the 
extent and severity of acute myocardial ischemia, as 
reflected in the distribution and amplitude of epi- 
cardial electrograms, in response to the acute intra- 
venous administration of ouabain immediately pre- 
ceding a 20-minute coronary artery ligation. With 
the use of the same preparation, however, Watanabe 
et a1.3s reported that the acute intravenous adminis- 
tration of ouabain to anesthetized dogs with acute 
pentobarbital-induced left ventricular failure 
caused a reduction in the extent and severity of 
temporary acute myocardial ischemia. In anesthe- 
tized dogs subjected to serial lo-minute coronary 
artery occlusions, Rude et a1.39 concluded that mod- 
erate inotropic stimulation with intravenous bolus 
injections of ouabain did not increase the severity of 
the brief episodes of regional ischemia, provided 
that neither heart rate nor rate-pressure product 
was increased. In a recent report, Alker and Kloner*O 
demonstrated that an intravenous bolus administra- 
tion of digoxin early during a complete 6-hour 
coronary artery ligation in anesthetized dogs failed 
to alter the size of the resulting myocardial infarct 
compared to vehicle-treated control dogs. However, 
the myocardial infarct sizes attained in the vehicle- 
and digoxin-treated animals in the complete coro- 
nary ligation model approximated 90% of the area 
at risk of infarction, suggesting little possibility to 
demonstrate a significant extension of necrotic dam- 
age with an intervention.40 
In the present investigation, the effects of digoxin 
pretreatment on the extent of evolving myocardial 
infarction were evaluated in an anesthetized canine 
preparation subjected to 60 minutes of regional 
myocardial ischemia, followed by reperfusion of the 
ischemic area for 6 hours. The duration of myocar- 
dial ischemic injury used in the present study has 
been shown by Eng and et al.36 to correspond to a 
rapid period of progression of myocardial necrosis in 
the dog. Therefore, the go-minute coronary artery 
occlusion period should be optimum for demonstrat- 
ing the ability of an intervention to increase/acceler- 
ate or decrease/retard the extent of evolving myo- 
cardial ischemic injury. In this study, pretreatment 
with digoxin to yield serum concentrations in the 
upper range of clinically therapeutic values was 
associated with significant increases in anatomic 
infarct size after regional myocardial ischemic- 
reperfusion injury compared to untreated control 
preparations. Myocardial infarct sizes in both the 
digoxin-pretreated and untreated control animals 
were correlated most significantly with regional 
myocardial blood flow during ischemia. Previous 
investigators have stressed the dependence of evolv- 
ing myocardial infarct size on the magnitude of 
ischemic collateral blood flo~.~,‘~ For both treat- 
ment groups in the present study, the regression 
lines for infarct size and ischemic blood flow were 
parallel and did not overlap, indicating that a signif- 
icant difference in evolving myocardial infarct sizes 
existed between the two groups, but this difference 
was not attributable to differences in the magnitude 
of collateral flow in the central ischemic area (i.e., 
equivalent degrees of ischemia had been attained in 
the two groups). The anatomic area at risk of 
infarction was not altered by digoxin pretreatment 
in the present study; neither did myocardial infarct 
sizes in either treatment group correlate significant- 
ly with area at risk. The reported degree of relation- 
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ship between infarct size and area at risk has varied 
in previous investigations,7,sg l4 with the failure of 
infarct size to correlate significantly with area at risk 
in one previous study having been attributed to a 
relatively narrow range of risk regions evaluated.8 A 
similarly narrow range of areas at risk of infarction 
was encountered in the present study. 
Conclusions. Pretreatment with digoxin to achieve 
serum concentrations in the upper range of clinically 
therapeutic values was associated with a significant 
increase in posterolateral myocardial infarct size in 
anesthetized dogs subjected to 60 minutes of left 
circumflex coronary artery occlusion, followed by 6 
hours of reperfusion. Regional myocardial blood 
flow tended to be reduced in digoxin-pretreated 
dogs compared to untreated control animals during 
baseline testing and was significantly reduced in 
anterior subendocardial sites in digoxin-pretreated 
animals during regional myocardial ischemia and 
reperfusion, suggesting that digoxin may have limit- 
ed subendocardial coronary blood flow. No marked 
global hemodynamic differences were noted 
between digoxin-pretreated and untreated control 
animals that could account for a significantly 
enhanced myocardial oxygen demand in the pres- 
ence of digoxin. Further studies with the use of 
estimates of regional contractile function and myo- 
cardial oxygen supply and demand are required to 
characterize the metabolic cost of therapeutic digox- 
in during regional myocardial ischemic injury. These 
findings suggest that an exacerbation of evolving 
myocardial ischemic injury, resulting in an increase 
in infarct size, may occur in the presence of clinically 
relevant serum digoxin concentrations. 
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MaMgement of patients with prolonged 
ischgmic chest pain without acute myocardial 
infarction 
Consecutive patients admitted to a Coronary Care Unit during 1981-1982 were studied. One 
hundred twenty-eight patients had prolonged ischemic chest pain without developing myocardial 
infarction. Fokow-up informatlon was available in 121 at an average period of 38 months. 
Thirty-eight patients (32.8%) sustained significant cardiovascular events, including 14 cardiac 
deaths. Only 15 patients were symptom-free off treatment. Prognosis was best determlned from 
the resting ECG. Translent ST-T wave shifts predicted patients at high risk of further 
cardiovascular events and allowed selection of a group meriting more tntensive treatment. (AM 
HEART J 1988;115:1182.) 
J. A. Wilson, M.R.C.P., and J. B. Irving, B.Sc., F.R.C.P. West Lothian, Scotland 
Unstable angina is an imprecise term describing a 
symptom complex intensively investigated by cardi- 
ologists in the last 10 to 15 years. The dilemmas in 
the management of patients with these symptoms 
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have been reviewed recently.’ Guidelines for treat- 
ment in large hospitals, with ready access to arteri- 
ography, angioplasty, and surgery, are not applica- 
ble to smaller hospitals, remote from such facilities. 
This study was designed to identify patients who 
merited referral for urgent investigation from a 
general hospital admitting approximately 650 
patients per annum to a four-bed Coronary Care 
Unit (CCU). The study was limited to a subgroup of 
“unstable angina” patients admitted with prolonged 
